Altropane Dose for Imaging Patients With Suspected Parkinson's Disease

NCT ID: NCT05636852

Last Updated: 2025-07-15

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-04-24
• Study Completion Date: 2024-06-08

Brief Summary

Previous studies showed that a dose of 8 millicuries of Altropane was appropriate for imaging patients with suspected Parkinson's disease. This study determined if a lower dose (5 millicuries) would suffice.

Conditions

Parkinson Disease; Movement Disorders

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Altropane (123I) Injection

Group Type: EXPERIMENTAL

Altropane (123I) Injection

Intervention Type: DRUG

Each participant received a single intravenous (IV) administration of 5 millicuries (mCi) (185 megabecquerels \[MBq\]) of Altropane (123I) Injection on Day 1. Altropane SPECT images were acquired for 30 minutes starting 15 to 20 minutes after administration with Altropane. These images were visually interpreted by 5 expert independent blinded readers.

Interventions

Altropane (123I) Injection

Each participant received a single intravenous (IV) administration of 5 millicuries (mCi) (185 megabecquerels \[MBq\]) of Altropane (123I) Injection on Day 1. Altropane SPECT images were acquired for 30 minutes starting 15 to 20 minutes after administration with Altropane. These images were visually interpreted by 5 expert independent blinded readers.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• For Part 1: a) the participant had a DaTscan image, obtained within 1 year (preferably within 6 months) before screening, that showed normal striatal uptake and b) the participant had a clinical diagnosis (made by a board-certified neurologist who was qualified by training and experience in the diagnosis of movement disorders) that was consistent with the DaTscan image.

For Part 2 (which was not conducted): a) the participant had a DaTscan image, obtained within 1 year (preferably within 6 months) before screening, that showed abnormal (unilateral or bilateral reduced) striatal uptake and b) the participant also had a confirmed clinical diagnosis of a dPS (such as Parkinson's disease, multiple system atrophy, corticobasal degeneration, progressive supranuclear palsy, etc.) made by a board-certified neurologist who was qualified by training and experience in the diagnosis of movement disorders, and c) the diagnosis was consistent with the DaTscan image.

• The participant was male or female, ≥18 years of age, of any race and ethnicity.
• The participant was able and willing to comply with study procedures and signed and dated informed consent was obtained.
• If the participant was a woman of childbearing potential*, she must have used a highly effective method of contraception** from Screening until 30 days after the last administration of Altropane, and the results of a serum or urine human chorionic gonadotropin (hCG) pregnancy test, performed at Screening and on the day of Altropane administration (with the result known before Altropane administration), must have been negative.

• A woman of childbearing potential was defined as neither post-menopausal nor surgically sterile. Post-menopausal means having had no menses for at least 12 months without an alternative medical cause. Surgically sterile means having had a documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy, or any combination of these.

** A highly effective method of contraception was defined as one that had a failure rate of less than 1% per year when used consistently and correctly; such methods included combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable); intrauterine device; intrauterine hormone-releasing system; bilateral tubal ligation/occlusion; vasectomized partner (with medical confirmation of success); and abstinence from heterosexual intercourse involving a woman of childbearing potential.

• If the participant was a male*** with a sexual partner who was a woman of childbearing potential*, he and his partner must have used adequate contraception** from Screening until 30 days after the last administration of Altropane.

(***A male was considered fertile after puberty unless permanently sterile by bilateral orchidectomy, or vasectomized with confirmation of success.)

Exclusion Criteria

• The participant was previously included in this study.
• Fewer than 7 disintegration half-lives had elapsed between the participant's last procedure (therapeutic or diagnostic) involving a radioisotope and Visit 2 (altropane SPECT imaging).
• Including participation in this study, the participant's total exposure to radiation during medical procedures/tests in the past year would have exceeded 50 mSv.
• The participant had participated in an investigational drug or device clinical trial within 30 days before the date of informed consent.
• The participant had any clinically significant or unstable physical or psychological illness, structural brain abnormality, abnormal laboratory results, or abnormal ECG (based on medical history or physical examination at Screening), as determined by the Principal Investigator, that would interfere with study participation.
• The participant had any history of drug or alcohol abuse in the 2 years prior to the date of informed consent.
• The participant had a positive urine screen for drugs of abuse at Screening.
• The participant was a pregnant or breast-feeding female, or was a female of child-bearing potential that was not using appropriate birth control.
• The participant was unable to lie supine for 1 hour.
• The participant had any thyroid disease other than adequately treated hypothyroidism.
• The participant had known or suspected allergy/hypersensitivity to any ingredient in Altropane or to the thyroid blocking medication to be used before imaging.
• The participant was taking any of the medications/treatments listed in the protocol as disallowed and could not or would not discontinue use at least 12 hours prior to SPECT exam.
• The participant was referred to DaTscan imaging for evaluation of possible cognitive impairment including dementia.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fortrea

INDUSTRY

Sponsor Role: collaborator

GE Healthcare

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Paul Sherwin, MD, PhD

Role: STUDY_DIRECTOR

GE Healthcare

Locations

Johns Hopkins University

Baltimore, Maryland, United States

Mayo Clinic

Rochester, Minnesota, United States

University of Mississippi Medical Center (UMMC)

Jackson, Mississippi, United States

University of Nebraska Medical Center

Omaha, Nebraska, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

GE-278-001

Identifier Type: -

Identifier Source: org_study_id